# Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution

> **NCT01429090** · PHASE1 · COMPLETED · sponsor: **University Medicine Greifswald** · enrollment: 12 (actual)

## Conditions studied

- Neurogenic Bladder

## Interventions

- **PROCEDURE:** blood sampling
- **DRUG:** Vagantin®
- **DRUG:** methantheline solution
- **PROCEDURE:** Measurement of salivation
- **PROCEDURE:** Measurement of accommodation
- **PROCEDURE:** Pupillometry

## Key facts

- **NCT ID:** NCT01429090
- **Lead sponsor:** University Medicine Greifswald
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** 1999-11
- **Final completion:** 2000-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2011-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01429090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01429090, "Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01429090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*